@AndrewGutwein Thank you for the clarification. This had been on my mind for some time, especially since I noticed that some programs list a Chairman’s letter or an IMSEL as a requirement on their websites.
Happy to share that our manuscript titled ‘Letter to the Editor: Risankizumab Is Effective for The Management of Crohn's Disease of the Pouch’ has been accepted for publication in the Inflammatory Bowel Disease journal.
Excited to share that 9 of our team’s research projects have been accepted, 2 of which I had the privilege to work on. Thank you, Dr. Ratnani, for being an amazing mentor!
Thank you, @adelkhan24, for the pleasure of meeting you today and reconnecting with a familiar face. I’d like to extend special recognition to @NowsherwanK for his leadership and dedication to this project. It was an honor to represent @KMC_pesh at @MethodistHosp Sepsis Symposium